gip glp 1 agonist tirzepatide Unveiling Tirzepatide's Therapeutic Spectrum: A Dual GIP/GLP-1 Targeting Metabolic, Neurological, and Cardiovascular Health The B12 Store Pembroke Pines

In the phase 2 study of type-2 diabetic patients, Tirzepatide produced a profound reduction in body weight and improved HbA1c levels, both of which were superior relative to effects of Dulaglutide in the active comparator arm [939], thus demonstrating the translation of the preclinical observations

Major cardiovascular events were also reduced by 18% (HR 0.82, 95% CI 0.680.98)

doi: 10.1016/j.neuint.2020.104707 [DOI] [PubMed] [Google Scholar] 12

As more GLP-1 prescriptions are written to manage not just diabetes and cardiovascular disease but also obesity, a key question emerges: What is the role of patient engagement and chronic disease management when prescribing these drugs

In addition to GLP-1 medications, interventions like bariatric surgery fall under the medicinal pillar

Allingbjerg, M.-L., Hansen, S